NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AEON

AEON Biopharma Inc

Jul 11 • 04:00PM ET

0.8400

Dollar change -0.0200
Percentage change -2.33	%

Healthcare • Biotechnology • USA • AMEX

Peers: JNJ PFE REGN LLY MRK ABT NVS BMY GILD BIIB

Scroll to Statements

Index	-	P/E	0.00	EPS (ttm)	298.98	Insider Own	21.76%	Shs Outstand	10.54M	Perf Week	0.29%
Market Cap	9.50M	Forward P/E	-	EPS next Y	-	Insider Trans	7.42%	Shs Float	8.85M	Perf Month	-3.75%
Enterprise Value	13.65M	PEG	-	EPS next Q	-	Inst Own	13.50%	Short Float	5.67%	Perf Quarter	97.28%
Income	169.12M	P/S	-	EPS this Y	-	Inst Trans	1.85%	Short Ratio	0.59	Perf Half Y	-97.95%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	2009.60%	Short Interest	0.50M	Perf YTD	-97.84%
Book/sh	-1.07	P/C	0.91	EPS next 5Y	-	ROE	-	52W High	269.28 -99.69%	Perf Year	-98.81%
Cash/sh	0.92	P/FCF	-	EPS past 3/5Y	56.96% -	ROIC	5490.84%	52W Low	0.38 124.00%	Perf 3Y	-99.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.21% 10.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	200.21%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.98	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.43	EPS Q/Q	101.00%	SMA20	3.67%	Beta	0.71	Target Price	360.00
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	27.05%	Rel Volume	0.10	Prev Close	0.86
Employees	5	LT Debt/Eq	-	Earnings	May 14 AMC	SMA200	-96.39%	Avg Volume	848.54K	Price	0.84
IPO	Apr 12, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	88,434	Change	-2.33%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-23	Initiated	H.C. Wainwright	Buy	$18

May-23-25 04:05PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +13.67%
May-19-25 04:05PM	AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 (GlobeNewswire)
May-14-25 04:05PM	AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-25-25 04:05PM	AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) -6.43%
Apr-21-25 04:10PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
04:05PM	Loading…
04:05PM	AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer (GlobeNewswire)
Mar-27-25 04:05PM	AEON Biopharma Announces CEO Transition (GlobeNewswire) -8.56% -7.34%
Mar-24-25 04:05PM	AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +8.03% -7.28%
Mar-04-25 08:00AM	AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -21.31%
Feb-24-25 02:00PM	AEON Biopharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -43.89%
Feb-07-25 04:05PM	AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) -6.93%
Jan-07-25 09:37AM	AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering (GlobeNewswire) +5.24%
Jan-06-25 09:00AM	AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering (GlobeNewswire) -63.09%
Jan-03-25 08:02PM	AEON Biopharma, Inc. Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-13-24 04:05PM	AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.11% -11.35%
08:00AM	Loading…
Sep-30-24 08:00AM	AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting (GlobeNewswire) +13.18%
Aug-21-24 09:55AM	AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-19-24 04:05PM	AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (GlobeNewswire)
Aug-12-24 04:05PM	AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-09-24 08:00AM	AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450 (GlobeNewswire) +7.84%
May-29-24 09:35AM	Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround (Zacks) +8.70%
08:00AM	AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan (GlobeNewswire)
May-14-24 04:05PM	AEON Biopharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 09:35AM	AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.21%
08:00AM	AEON Biopharma Provides Update on Development Pipeline (GlobeNewswire)
May-03-24 04:08PM	US Equity Markets Close Higher Friday Following Weak Jobs Report (MT Newswires) -49.40%
03:55PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires)
02:37PM	Top Midday Decliners (MT Newswires)
09:05AM	Sector Update: Health Care Stocks Mixed Pre-Bell Friday (MT Newswires)
08:31AM	AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial (MT Newswires)
07:00AM	Loading…
07:00AM	AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine (GlobeNewswire)
Mar-30-24 10:53PM	CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
Mar-29-24 04:15PM	AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
03:45PM	AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 04:30PM	AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine (GlobeNewswire) -11.60% -12.57%
04:29PM	AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements (GlobeNewswire)
Jan-18-24 04:05PM	AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference (GlobeNewswire) +10.35%
Dec-12-23 08:00AM	AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine (GlobeNewswire)
Nov-15-23 04:49AM	AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements (GuruFocus.com) +7.61%
Nov-13-23 08:15AM	AEON Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 04:05PM	AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine (GlobeNewswire)
Aug-29-23 08:00AM	AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress® (GlobeNewswire)
Aug-24-23 08:00AM	AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache (GlobeNewswire) +14.91%
Aug-16-23 07:00AM	Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma (GlobeNewswire) +7.06%
Jul-24-23 07:00AM	AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update (GlobeNewswire) -15.13%

AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FISCHER JOST	Director	May 21 '25	Buy	0.49	60,000	29,250	266,785	May 23 04:46 PM
FISCHER JOST	Director	May 20 '25	Buy	0.51	60,000	30,360	206,785	May 21 04:50 PM
FISCHER JOST	Director	May 19 '25	Buy	0.50	50,000	24,940	146,785	May 21 04:50 PM
Oleg Grodnensky	Affiliate	Jul 29 '24	Proposed Sale	2.63	201,825	530,780		Jul 29 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AEON

AEON Biopharma Inc

Upgrade your FINVIZ experience